Definium Therapeutics, Inc. (NASDAQ:DFTX) Stock Has Consensus Target Price of $64.88

Definium Therapeutics, Inc. (NASDAQ:DFTX) has earned an average recommendation of “Buy” from the twenty-one analysts that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, eighteen have assigned a buy rating and two have assigned a strong buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $64.88.

Several research firms have recently weighed in on DFTX. Wells Fargo & Company boosted their price target on Definium Therapeutics from $68.00 to $72.00 and gave the stock an “overweight” rating in a report on Thursday, August 13th. JonesTrading lifted their target price on shares of Definium Therapeutics from $74.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, August 13th. Wall Street Zen lowered shares of Definium Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. Oppenheimer restated an “outperform” rating and issued a $75.00 price target on shares of Definium Therapeutics in a research report on Monday, September 14th. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and set a $66.00 price target on shares of Definium Therapeutics in a research note on Friday, September 11th.

Definium Therapeutics Stock Down 0.5%

Shares of DFTX opened at $37.40 on Friday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.95 and a current ratio of 6.95. Definium Therapeutics has a 52 week low of $10.46 and a 52 week high of $49.70. The stock has a market capitalization of $5.03 billion, a price-to-earnings ratio of -10.90 and a beta of 2.19. The stock has a fifty day moving average of $41.03 and a 200-day moving average of $32.37.

Definium Therapeutics (NASDAQ:DFTX) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($1.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.89). As a group, sell-side analysts anticipate that Definium Therapeutics will post -3.02 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Definium Therapeutics news, CFO Brandi Roberts sold 3,377 shares of Definium Therapeutics stock in a transaction dated Friday, September 25th. The stock was sold at an average price of $36.57, for a total transaction of $123,496.89. Following the transaction, the chief financial officer directly owned 394,528 shares of the company’s stock, valued at approximately $14,427,888.96. The trade was a 0.85% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Robert Barrow sold 31,550 shares of the company’s stock in a transaction dated Friday, September 25th. The shares were sold at an average price of $36.57, for a total value of $1,153,783.50. Following the completion of the sale, the chief executive officer owned 2,213,090 shares in the company, valued at $80,932,701.30. This trade represents a 1.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 71,098 shares of company stock valued at $2,626,115. Company insiders own 2.40% of the company’s stock.

Hedge Funds Weigh In On Definium Therapeutics

Hedge funds have recently made changes to their positions in the stock. Avoro Capital Advisors LLC bought a new stake in Definium Therapeutics in the fourth quarter valued at approximately $66,950,000. Wellington Management Group LLP acquired a new position in shares of Definium Therapeutics in the 2nd quarter worth approximately $138,755,000. Bank of New York Mellon Corp boosted its stake in shares of Definium Therapeutics by 3.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 777,271 shares of the company’s stock valued at $36,563,000 after purchasing an additional 24,349 shares during the last quarter. Royce & Associates LP increased its position in shares of Definium Therapeutics by 102.5% during the fourth quarter. Royce & Associates LP now owns 164,041 shares of the company’s stock worth $2,197,000 after buying an additional 83,017 shares during the period. Finally, Seven Fleet Capital Management LP acquired a new stake in shares of Definium Therapeutics during the second quarter worth $6,992,000. 27.91% of the stock is currently owned by institutional investors.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.